Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Semaglutide vs Tirzepatide
Peptide Schedule Research TeamReviewed Oct 13, 202614 Citations
Semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist. Tirzepatide (Zepbound, Mounjaro) activates both the GIP and GLP-1 receptors. SURMOUNT-5 put the two head-to-head for 72 weeks.
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix. In SURMOUNT-5 (PMID 40353578, n=751), semaglutide produced 13.7% weight loss versus 20.2% for tirzepatide at 72 weeks, with everyone on the highest dose they tolerated. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (PMID 37952131, n=17,604) confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.
View full guide →20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone. SURMOUNT-1 (PMID 35658024, n=2,539) showed dose-dependent results at 72 weeks. Its treatment-regimen estimand counts everyone randomized, including people who stopped the drug. On that basis, mean weight loss was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% on placebo. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight. The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.
View full guide →At a Glance
| Attribute | ||
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Safety Grade | A | A |
| Half-Life | ~7 days | ~5 days |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5 mg, 10 mg | 5 mg, 10 mg, 15 mg |
| Beginner Dose | 250 mcg Weekly | 2.5 mg Weekly |
| Moderate Dose | 500 mcg Weekly | 5 mg Weekly |
| Aggressive Dose | 2.4 mg Weekly | 15 mg Weekly |
| Dosing Source | FDA Label | FDA Label |
| Side Effects | Black box warning: semaglutide causes thyroid C-cell tumors in rodents. Whether it causes medullary thyroid carcinoma in humans is unknown. Anyone with a personal or family history of MTC or MEN2 cannot use this drug. That warning is printed on every Wegovy and Ozempic label, and it stays there. GI side effects dominate the titration period. Nausea hits 40 to 50% of patients during the first weeks at each new dose level. For some, that nausea is severe enough to impact daily function and work productivity. Community consensus recommends extending each titration step to 6 to 8 weeks rather than 4 if nausea is bad. The nausea typically fades within the first week at each stable dose. Constipation hit 24% of adults on Wegovy 2.4 mg in the label's weight trials (11% on placebo). Community reports describe it as common with long-term use. Proactive fiber supplementation (psyllium husk from day one) is the top community recommendation. Magnesium citrate at 200 to 400 mg before bed serves as the standard backup. Vomiting and diarrhea also occur, usually transiently during dose escalation. Rare but serious: pancreatitis requires immediate emergency evaluation if you experience severe abdominal pain radiating to the back. Gallbladder disease (cholelithiasis, cholecystitis) is a known complication, particularly with rapid weight loss. Acute kidney injury can result from dehydration driven by persistent GI symptoms. The US labels flag three more signals. Ileus (intestinal obstruction) appears in postmarketing reports and requires emergency care if you develop severe persistent abdominal pain. Diabetic retinopathy complications can paradoxically worsen with rapid A1c improvement in patients with pre-existing retinopathy. Resting heart rate increases a mean 1 to 4 bpm. In the Wegovy weight trials, 26% of users (vs 16% on placebo) had a rise of 20 bpm or more at some visit. NAION (non-arteritic anterior ischemic optic neuropathy) is a separate, rarer eye signal. It's a loss of blood flow to the front of the optic nerve that can cause sudden, painless vision loss, usually in one eye. A 2026 meta-analysis pooled 8 observational cohort studies covering 5,916,559 people (PMID 42612051). Semaglutide users had roughly double the risk (relative effect 1.93, 95% CI 1.22 to 3.08). The studies disagreed widely (I² 91%), and the link was significant in people with diabetes but not in the overweight or obesity subgroup. These are associations, not proof that semaglutide causes NAION. The current US Wegovy, Ozempic, and Rybelsus labels don't list it. Europe's EMA called it a very rare side effect in June 2025 (up to 1 in 10,000 people). Sudden vision loss or fast-worsening eyesight on semaglutide needs same-day medical care. The 7.2 mg Wegovy HD dose introduced a new signal, dysesthesia (altered skin sensation such as tingling or burning). In the label's trials it hit 22% of patients on 7.2 mg, vs 6% on 2.4 mg and 0.3% on placebo. Among those affected, 18% had not recovered by the end of the trial. Hair thinning from telogen effluvium peaks between months 3 and 6. It is a response to rapid weight loss, not a direct drug effect. It typically resolves by month 8 to 12 with adequate protein intake. Lean mass loss of 25 to 40% of total weight lost is documented without resistance training. "Ozempic face" (facial volume loss) becomes visible after 30+ lbs of weight loss. The label contraindications are a personal or family history of MTC or MEN2 and serious hypersensitivity to semaglutide. For weight loss, the label says to stop it in pregnancy, and at least 2 months before a planned pregnancy. It advises against breastfeeding on the tablets and doesn't recommend semaglutide with severe gastroparesis. A history of pancreatitis warrants a talk with your prescriber first. If you are on insulin or sulfonylureas, doses of those drugs typically need a 20 to 30% reduction at semaglutide initiation to prevent hypoglycemia. | Tirzepatide carries a black box warning for thyroid C-cell tumors. In rodent studies, it caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this translates to humans is unknown, and no confirmed human cases have been attributed to tirzepatide. The drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Gastrointestinal side effects are the most common reason people struggle with tirzepatide. In the SURMOUNT and SURPASS trials, nausea affected 12 to 29% of patients (dose-dependent, worst at higher weight-management doses). Diarrhea occurred in 13 to 17%. Vomiting hit 8 to 10%. Constipation affected 7 to 11%. Most of these effects are mild-to-moderate and improve with slow dose titration; the community-preferred 6 to 8 week steps between dose increases reduce GI burden compared to the FDA label's 4-week minimum. Decreased appetite (9 to 11%) is technically a side effect, though most users consider it the primary benefit. Sulfur burps are a community-reported nuisance during escalation phases that clinical trials don't track well. Hair thinning (telogen effluvium) affects roughly 4 to 5% of users versus about 1% on placebo. This isn't a direct drug effect. Rapid weight loss and caloric restriction trigger a hair growth cycle shift that typically starts 2 to 3 months in and resolves on its own by month 9 to 12. Injection-site reactions occur in 4 to 7% of patients. Rotating injection sites between the abdomen, thigh, and upper arm helps. Let the vial reach room temperature for 15 to 20 minutes before injecting. Pancreatitis is rare but serious. Severe, persistent abdominal pain warrants immediate medical evaluation. Serum lipase testing should happen only when pancreatitis is clinically suspected; routine screening isn't indicated. Gallbladder disease and hypersensitivity reactions are uncommon but documented in clinical trials. Stop tirzepatide and seek medical care if you develop signs of anaphylaxis, severe abdominal pain, or jaundice. Low blood pressure is a smaller but real signal. On the Zepbound label, hypotension hit 1.6% on tirzepatide vs 0.1% on placebo in the pooled weight-loss trials. It ran higher in people also taking blood pressure medication (2.2% vs 1.2% without it) and showed up alongside gastrointestinal side effects and dehydration. A 2026 meta-analysis pooled 32 randomized trials of tirzepatide and semaglutide (47,332 people, PMID 42603240). Tirzepatide carried 2.45 times the risk of hypotension-related events (95% CI 1.35 to 4.45). The risk rose at higher doses, and semaglutide showed no significant change. Lightheadedness when you stand up is worth a blood pressure check, especially if you take antihypertensives. Muscle loss is a legitimate concern. Approximately 25% of weight lost on tirzepatide is lean mass (SURMOUNT-1 body composition data). Resistance training 3 to 4 times per week and protein intake of at least 1.2 g/kg body weight per day are the primary countermeasures. Pregnancy and breastfeeding: tirzepatide is contraindicated. Stop treatment at least 2 months before planned conception due to the 5-day half-life and limited reproductive safety data. |
Key Differences
Head-to-head, tirzepatide won by 6.5 percentage points. In SURMOUNT-5 (NEJM 2025)[1], 751 adults with obesity and no diabetes took tirzepatide or semaglutide at the highest dose they tolerated for 72 weeks. Mean weight change was 20.2% vs 13.7%. The trial was open-label.
The placebo-controlled trials point the same way but are separate studies. STEP 1 (n=1,961)[2] reported 14.9% at 68 weeks. SURMOUNT-1 (n=2,539)[3] reported 20.9% at 15 mg over 72 weeks.
Semaglutide activates the GLP-1 receptor. Tirzepatide activates the GIP receptor as well; its label lists it as a GIP and GLP-1 receptor agonist. The second receptor is the usual explanation for the larger average loss, but the trials did not test why.
Dosage comparison, from the labels. Wegovy starts at 0.25 mg weekly and rises every four weeks through 0.5, 1 and 1.7 mg to 2.4 mg at week 17. The label also allows 1.7 mg for maintenance. Zepbound starts at 2.5 mg weekly for four weeks. It then rises in 2.5 mg steps, each after at least four weeks, to a 5, 10 or 15 mg maintenance dose.
Label nausea rates come from separate placebo-controlled trials and do not compare the two drugs. Zepbound: 25% at 5 mg, 29% at 10 mg, 28% at 15 mg, vs 8% on placebo. Wegovy: 44% vs 16% on placebo. Head-to-head in SURMOUNT-5, gastrointestinal events were the most common side effects with both drugs [1].
Semaglutide has the cardiovascular outcomes trial in obesity: SELECT (n=17,604)[4] cut major cardiovascular events by 20% (hazard ratio 0.80). Tirzepatide's SURPASS-CVOT [5] was in type 2 diabetes and showed non-inferiority to dulaglutide. No tirzepatide outcomes trial in obesity has reported.
Semaglutide came first: Ozempic on December 5, 2017 (type 2 diabetes), then Wegovy on June 4, 2021 (obesity). Tirzepatide followed as Mounjaro on May 13, 2022 (type 2 diabetes) and Zepbound on November 8, 2023 (obesity). Both molecules carry the thyroid C-cell boxed warning.
Semaglutide has the higher-dose and oral options. Wegovy HD 7.2 mg was approved on March 19, 2026, and in STEP UP [6] it produced 18.7% weight loss at 72 weeks vs 3.9% on placebo. Wegovy tablets were approved on December 22, 2025; OASIS 4 [7] reported 13.6% at 64 weeks on 25 mg.
When to Choose Semaglutide
Cardiovascular risk reduction matters (SELECT, on the Wegovy label)
A tablet, or the longer obesity record (Wegovy, approved 2021), is preferred
Weight loss on semaglutide already meets the goal
An adverse reaction to tirzepatide rules it out
When to Choose Tirzepatide
The larger average weight loss is the goal (20.2% vs 13.7% in SURMOUNT-5)
Semaglutide produced less than hoped
Blood sugar and insulin sensitivity are secondary goals (dual GIP and GLP-1 action)
Verdict
Tirzepatide produced more weight loss head-to-head (20.2% vs 13.7% in SURMOUNT-5); gastrointestinal side effects were the most common with both. Semaglutide has the cardiovascular outcomes trial in obesity, a tablet, and a 7.2 mg dose. Community reports mirror the trial: people who switched from semaglutide to tirzepatide describe stronger appetite control, and cost or coverage decides for most.
Research peptides with both sides of the evidence.
Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.
Can You Stack Semaglutide + Tirzepatide?
Not together. Tirzepatide already activates the GLP-1 receptor, so adding semaglutide stacks two agonists on one receptor. The Wegovy label says coadministration with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says the same. No trial has tested the pair. Switching is a prescriber decision made on response, tolerability and coverage.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Related Guides & Stacks
Peptide Schedule Research TeamReviewed Oct 13, 202614 Citations
References
- [1]SURMOUNT-5: tirzepatide vs semaglutide for obesity, 72 weeks (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]STEP 1: semaglutide 2.4 mg vs placebo, 68 weeks (NEJM 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]SURMOUNT-1: tirzepatide once weekly for obesity, 72 weeks (NEJM 2022) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]SELECT: semaglutide and cardiovascular outcomes in obesity without diabetes (NEJM 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]SURPASS-CVOT: cardiovascular outcomes with tirzepatide vs dulaglutide in type 2 diabetes (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]STEP UP: once-weekly semaglutide 7.2 mg in adults with obesity (Lancet Diabetes Endocrinol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]OASIS 4: oral semaglutide 25 mg in adults with overweight or obesity (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Wegovy (semaglutide) prescribing information, DailyMed (opens in a new tab)FDA Label
- Zepbound (tirzepatide) prescribing information, DailyMed (opens in a new tab)FDA Label
- Drugs@FDA: Ozempic, NDA 209637 (approved December 5, 2017) (opens in a new tab)FDA Label
- Drugs@FDA: Wegovy, NDA 215256 (approved June 4, 2021; 7.2 mg supplement approved March 19, 2026) (opens in a new tab)FDA Label
- Drugs@FDA: Wegovy tablets, NDA 218316 (approved December 22, 2025) (opens in a new tab)FDA Label
- Drugs@FDA: Mounjaro, NDA 215866 (approved May 13, 2022) (opens in a new tab)FDA Label
- Drugs@FDA: Zepbound, NDA 217806 (approved November 8, 2023) (opens in a new tab)FDA Label